The government health service has said that it definitely will not pay for patients to take the influenza medicine Antinfia until the drug’s manufacturer, PharmCo, provides detailed information about Antinfia’s cost-effectiveness. PharmCo has responded that obtaining such information would require massive clinical trials. These trials cannot be performed until the drug is in widespread circulation, something that will happen only if the government health service pays for Antinfia.

If the statements of both the government health service and PharmCo are true, which one of the following is most likely to also be true?